Utility of the Mild Brain Injury Atypical Symptoms Scale to detect symptom exaggeration: an analogue simulation study

Rael T Lange1, Shannon L Edmed, Karen A Sullivan

  • 1Defense and Veterans Brain Injury Center, North Bethesda, MD, USA. rlange@dvbic.org

Insights

The Mild Brain Injury Atypical Symptoms Scale (mBIAS) can help detect symptom exaggeration in postconcussional disorder (PCD) and posttraumatic stress disorder (PTSD) screenings. This scale aids in identifying potential malingering when using the NSI and PCL-C measures.

Area of Science:

  • Neuroscience
  • Psychology
  • Forensic Psychology

Background:

  • Self-report symptom checklists for postconcussional disorder (PCD) and posttraumatic stress disorder (PTSD) are prone to symptom exaggeration.
  • Detecting malingering is crucial for accurate diagnosis and treatment planning.

Purpose of the Study:

  • To evaluate the utility of the five-item Mild Brain Injury Atypical Symptoms Scale (mBIAS) in detecting symptom exaggeration.
  • To assess the mBIAS's effectiveness when used with the Neurobehavioral Symptom Inventory (NSI) and the PTSD Checklist-Civilian (PCL-C).

Main Methods:

  • 85 Australian undergraduate students participated under control, feign PCD, or feign PTSD conditions.
  • Participants completed the mBIAS, NSI, PCL-C, MMPI-2-RF, and SIMS.
  • Statistical analyses compared scores between groups to identify differences and optimal cutoff points.

Main Results:

  • Participants feigning PCD or PTSD scored significantly higher on the mBIAS, NSI, PCL-C, and MMPI-2-RF compared to controls.
  • Optimal mBIAS cutoff scores of ≥8 and ≥6 indicated probable and possible symptom exaggeration, respectively, with high specificity.
  • Few differences were observed between feigning PCD and PTSD groups, except on the NSI and PCL-C.

Conclusions:

  • The mBIAS shows preliminary support as a tool to detect symptom exaggeration in PCD and PTSD assessments.
  • The findings suggest the mBIAS can enhance the validity of self-report measures like the NSI and PCL-C.
  • Further research is warranted to confirm the mBIAS's efficacy across diverse populations.

Related Concept Videos